ReviewNature reviews. Cardiology2021
Interplay between inflammation and thrombosis in cardiovascular pathology.
Review in Nature reviews. Cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 582 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
582 citing papers in PubMed.
- Platelet count polygenic scores may modify the effect of aspirin in primary prevention of dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Trial
- Inflammation and day-to-day occurrence of atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Trial
- Platelets and inflammation-insights from platelet non-coding RNA content and release in the Bruneck study and the PACMAN-AMI trial.Cardiovascular research · 2025Trial
- Plasma chemokines indicate enhanced bleeding in patients with chronic coronary syndrome undergoing percutaneous coronary stenting.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Trial
- Potential association of TGFβ1 plasma levels and fibrinolysis parameters with the risk of recurrence and vascular obstruction after a first unprovoked pulmonary embolism episode.Journal of thrombosis and thrombolysis · 2025Trial
- From barrier to guide: Exploiting disease-specific hemodynamics for enhanced nanodrug targeting in cardiovascular diseases.Pharmaceutical science advances · 2026Review
- Hypercoagulability and vascular proinflammatory activation promote cardiac-cerebral fibrinogenesis in a rodent model of Chagas disease.Emerging microbes & infections · 2026Article
- A Mitochondrial-Related Gene Signature for Diagnosis and Immune Microenvironment Modulation in Lung Cancer and Venous Thromboembolism.World journal of oncology · 2026Article
- Spatiotemporal regulation of neutrophil-mediated immune cascades via engineered PEEK surfaces restores osseointegration in diabetes.Bioactive materials · 2026Article
- Antiphospholipid antibodies and cardiovascular thrombosis.Nature reviews. Cardiology · 2026Review
- Assembly of Bioactive Superstructures via Metal-Phenolic Complexation for Blood Purification.Angewandte Chemie (International ed. in English) · 2026Article
- Comparative Prognostic Performance of Platelet-Containing and Platelet-Free Inflammatory Indices After Percutaneous Coronary Intervention.Journal of clinical medicine · 2026Article
- CAREPath: semantic context-aware reasoning paths with mechanism-augmented embeddings for drug repurposing.Briefings in bioinformatics · 2026Article
- The Cancer Immunotherapy Thromboembolism Assessment: A Novel Score for Predicting Thromboembolic Events in Melanoma Patients Treated With Immune Checkpoint Inhibition.International journal of cancer · 2026Article
- Emerging evidence of neutrophil extracellular traps in essential hypertension and target organ damage: pathophysiological insights and therapeutic implications.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Review
- Selected biomarkers of coagulation, inflammation, and vascular tone in young women with normal weight obesity.International journal of obesity (2005) · 2026Article
- Beyond Lesions: Systemic Inflammatory and Metabolic Characterization of Swine Inflammation and Necrosis Syndrome.Animals : an open access journal from MDPI · 2026Article
- Cell Membrane-Coated Biomimetic Nanocarriers for Plaque-Targeted Atherosclerosis Therapy: Molecular Mechanisms, Inflammatory Microenvironments, and Translational Challenges.International journal of molecular sciences · 2026Review
- Targeting Inflammation Across the Myocardial Infarction Continuum: Biomarkers, Imaging, and Emerging Therapies.Journal of clinical medicine · 2026Review
- Residual Atherothrombotic Risk After Myocardial Infarction: Integrating Lipid, Inflammatory and Thrombotic Pathways.Journal of clinical medicine · 2026Review
522 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thrombosis is the most feared complication of cardiovascular diseases and a main cause of death worldwide, making it a major health-care challenge. Platelets and the coagulation cascade are effectively targeted by antithrombotic approaches, which carry an inherent risk of bleeding. Moreover, antithrombotics cannot completely prevent thrombotic events, implicating a therapeutic gap due to a third, not yet adequately addressed mechanism, namely inflammation. In this Review, we discuss how the synergy between inflammation and thrombosis drives thrombotic diseases. We focus on the huge potential of anti-inflammatory strategies to target cardiovascular pathologies. Findings in the past decade have uncovered a sophisticated connection between innate immunity, platelet activation and coagulation, termed immunothrombosis. Immunothrombosis is an important host defence mechanism to limit systemic spreading of pathogens through the bloodstream. However, the aberrant activation of immunothrombosis in cardiovascular diseases causes myocardial infarction, stroke and venous thromboembolism. The clinical relevance of aberrant immunothrombosis, referred to as thromboinflammation, is supported by the increased risk of cardiovascular events in patients with inflammatory diseases but also during infections, including in COVID-19. Clinical trials in the past 4 years have confirmed the anti-ischaemic effects of anti-inflammatory strategies, backing the concept of a prothrombotic function of inflammation. Targeting inflammation to prevent thrombosis leaves haemostasis mainly unaffected, circumventing the risk of bleeding associated with current approaches. Considering the growing number of anti-inflammatory therapies, it is crucial to appreciate their potential in covering therapeutic gaps in cardiovascular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.